Ahead 300

by BrainScope  · Based in United States → — Revolutionizing Brain Health with AI-Powered EEG Solutions
Emergency Medicine Neurology Sports Medicine

Contact for pricing
Regulatory Status Disclosed

Overview

The Ahead 300, later commercialized as BrainScope One, is a portable, non-invasive, non-radiation emitting, point-of-care medical device designed to aid clinicians in the rapid and objective assessment of traumatic brain injury (TBI), including concussions and brain bleeds. It utilizes proprietary, patent-protected electroencephalography (EEG) capabilities, advanced signal processing, sophisticated algorithms, and machine learning to analyze head-injured patient data. The device provides a multi-modal assessment, offering a comprehensive panel of data to assist in the diagnosis of the full spectrum of TBI. It is intended for use as an adjunct to standard clinical practice to aid in the evaluation of patients being considered for a head CT, who sustained a closed head injury within 72 hours, present with a Glasgow Coma Scale (GCS) score of 13-15, and are between the ages of 18-85 years. The Ahead 300 helps identify patients likely to have structural brain injury visible on a CT scan and can potentially reduce the number of unnecessary head CT scans in emergency departments.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered EEG analysis for TBI assessment
  • Identifies structural brain injuries (brain bleeds)
  • Assesses functional brain injuries (concussions)
  • Portable, handheld device with disposable electrode headset
  • Non-invasive and non-radiation emitting
  • Provides rapid, objective assessment at point of care
  • Reduces unnecessary head CT scans
  • Integrates advanced signal processing and machine learning
  • Offers a multi-modal, comprehensive panel of data
  • Actionable results downloadable to PDF

Use Cases

  • Emergency Departments for TBI evaluation
  • Urgent Care Centers for head injury assessment
  • Concussion Clinics for objective diagnosis
  • Military healthcare system for battlefield TBI assessment
  • Sports medicine settings for concussion management

What Physicians Need to Know

Stroke Detection Speed
While the Ahead 300 is primarily focused on traumatic brain injury, BrainScope's AI-driven platform and biomarkers are being developed for other CNS indications, including stroke, with applicability for early detection.
Brain MRI/CT Analysis
The Ahead 300 is designed to help clinicians determine the likelihood of a traumatic structural brain injury visible on a CT scan, and can potentially reduce unnecessary head CTs. It is not a substitute for a CT scan.
EEG Interpretation AI
The device leverages advanced signal processing, sophisticated algorithms, and machine learning to analyze EEG data, expanding the clinical utility of EEG to assess and subtype neurological diseases.
Neurodegenerative Disease Screening
BrainScope is dedicated to creating transformative biomarkers for a range of CNS indications, including neurodegenerative diseases, with applicability for early detection, tracking progression, and monitoring treatment effects.
Triage Prioritization Speed
The Ahead 300 provides rapid, objective assessment at the point of care, significantly improving triage and medical management for head-injured patients. It can lead to improvements in emergency department throughput due to reduced patient wait times.
Mobile Notification System
The Ahead 300 leverages state-of-the-art handheld smartphone technology and a proprietary disposable electrode headset. The device provides a summary report that can be shared with providers.
Physician Tip

The Ahead 300 is an adjunct to standard clinical practice and should not be used as a substitute for a CT scan. Clinical judgment should always be used when interpreting the device's outputs, and it should not be used as a stand-alone diagnostic device. It is intended for use in patients aged 18-85 with a Glasgow Coma Scale (GCS) score of 13-15 who have sustained a closed head injury within 72 hours and are being considered for a head CT. The device can help identify patients who are likely to have a structural brain injury visible on a CT scan, or those who may need further evaluation or observation. It also provides an objective marker of brain function impairment (Brain Function Index) and a Concussion Index to aid in evaluating concussion and tracking recovery.

The Ahead 300 utilizes a proprietary disposable electrode headset that connects to a handheld display device, which uses smartphone technology. BrainScope's AI solution can also be applied to EEG captured by third-party devices. Software updates for the BrainScope device are performed by BrainScope personnel.

Details

Category Neurology AI, Triage & ER/ICU AI
Pricing Contact for pricing
DeploymentCloud
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Emergency Medicine, Neurology, Sports Medicine

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2016-09-22K161068 510(k)Ahead 300

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Ahead 300

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Ahead 300.

Loading videos...

View all on YouTube

Frequently Asked Questions

The Ahead 300 is primarily used as an adjunct to standard clinical practice for the rapid and objective assessment of patients with mild head injuries, including concussions, within 72 hours of injury. It helps clinicians determine the likelihood of a traumatic structural brain injury visible on a CT scan and identify functional brain abnormalities.
The Ahead 300 utilizes sophisticated algorithms and machine learning to process electroencephalography (EEG) capabilities, aiding in the evaluation of head-injured patients with objective biomarkers of brain electrical activity. Neurology-specific concerns with AI in general include data privacy, potential for exacerbating health disparities if not carefully implemented, and the need for physicians to understand the power and limitations of these tools.
The Ahead 300 is a medical device that has received multiple FDA clearances, including its most advanced version in September 2016. It is indicated for use as an adjunct to standard clinical practice and should not be used as a substitute for a CT scan.
While the Ahead 300 offers a multi-modal assessment, other cognitive screening and assessment tools exist, ranging from traditional paper-based tests like the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Exam (MMSE) to other digital cognitive assessment platforms. Some AI tools focus on clinical decision support by reasoning from anatomical findings to disease, but may not directly assess imaging like CT or EEG.
The Ahead 300 is indicated for use in patients aged 18-85 years with a Glasgow Coma Scale score of 13-15, who sustained a closed head injury within 72 hours. It is crucial to remember that it is an adjunct to standard clinical practice and should not be used as a substitute for a CT scan.

Related Tools

syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
Neurophet AQUA AD Plus
Neurophet
Neurology AI
Neurophet AQUA AD Plus is an AI-powered brain imaging analysis software that supports the diagnosis, treatment guidance, and monitoring of Alzheimer's disease by analyzing MRI and PET scans.
myosmart trial kit
Otto Bock Healthcare Products GmbH
Neurology AI
The Ottobock MyoSmart Trial Kit assists clinicians in assessing and fitting advanced neurorehabilitation prosthetic and orthotic solutions.
connectgrip. (560X27-1)
Otto Bock Healthcare Products GmbH
Neurology AI
Otto Bock Healthcare Products GmbH offers advanced prosthetic and orthotic solutions, with 'connectgrip' (560X27-1) likely being a component designed for secure and functional connection within these systems, potentially incorporating intelligent features for enhanced user control.
myosmart.cuff (757M20-2)
Otto Bock Healthcare Products GmbH
Lab & Diagnostics
The myosmart.cuff is a medical device by Otto Bock Healthcare Products GmbH designed for objective measurement of muscle tone, primarily for use in neurological rehabilitation.
myosmart. (13E522)
Otto Bock Healthcare Products GmbH
Neurology AI
myosmart.

See all Neurology AI tools →

More from BRAINSCOPE COMPANY

Brainscope Ahead 200
BrainScope
Neurology AI
BrainScope TBI
BrainScope
Clinical Decision Support & Reference

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-03 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.